Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple …
…, C Fabio, R Lemoli, A Liberati, C Nozzoli, R Zambello… - The Lancet, 2019 - thelancet.com
Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone …
…, M Offidani, ID Vincelli, R Zambello… - The Lancet …, 2020 - thelancet.com
Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
…, R Ria, A Capaldi, R Zambello… - Blood, The Journal …, 2008 - ashpublications.org
The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT)
in newly diagnosed patients with myeloma showed significantly higher response rate and …
in newly diagnosed patients with myeloma showed significantly higher response rate and …
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
…, V Callea, S Pulini, AM Carella, R Zambello… - Journal of Clinical …, 2011 - ascopubs.org
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases
the risk of thromboembolic events. In this randomized, open-label, multicenter trial, we …
the risk of thromboembolic events. In this randomized, open-label, multicenter trial, we …
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and …
…, S Aquino, A Palmas, B Gamberi, R Zambello… - The Lancet …, 2021 - thelancet.com
… Renato Zambello … Statistical analyses were done with R (version 4.0.2). The data cutoff
date was Jan 7, 2021. … R-ISS=Revised ISS stage. del=deletion. t=translocation. …
date was Jan 7, 2021. … R-ISS=Revised ISS stage. del=deletion. t=translocation. …
Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of …
On the basis of recent clinical and experimental data, natural killer (NK) cells appear to play
a crucial role in eradication of acute myeloid leukemias. In the present study, by exploiting …
a crucial role in eradication of acute myeloid leukemias. In the present study, by exploiting …
The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis
G Semenzato, R Zambello… - Blood, The Journal …, 1997 - ashpublications.org
The lymphoproliferative disease of granular lymphocytes (LDGL), also referred to as LGL
leukemia, is a heterogeneous disorder, but is clinically, morphologically, and immunologically …
leukemia, is a heterogeneous disorder, but is clinically, morphologically, and immunologically …
[HTML][HTML] Insights into genetic landscape of large granular lymphocyte leukemia
…, VR Gasparini, G Semenzato, R Zambello - Frontiers in …, 2020 - frontiersin.org
Large granular lymphocyte leukemia (LGLL) is a chronic proliferation of clonal cytotoxic
lymphocytes, usually presenting with cytopenias and yet lacking a specific therapy. The disease …
lymphocytes, usually presenting with cytopenias and yet lacking a specific therapy. The disease …
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation …
…, A Falcone, C Nozzoli, R Zambello… - Blood, The Journal …, 2012 - ashpublications.org
In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates
and extended progression-free survival were demonstrated with bortezomib-thalidomide-…
and extended progression-free survival were demonstrated with bortezomib-thalidomide-…
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous …
…, R Zambello, R Paolini, A Menin, R Zanotti… - Journal of clinical …, 2013 - ascopubs.org
… In this phase II study, we combined cytarabine with R and B (R-BAC) in patients with MCL
age ≥ 65 years who were previously untreated or relapsed or refractory (R/R) after one prior …
age ≥ 65 years who were previously untreated or relapsed or refractory (R/R) after one prior …